Inhibrx Biosciences (NASDAQ:INBX) Trading 8.7% Higher - Should You Buy?

Inhibrx Biosciences, Inc. (NASDAQ:INBX - Get Free Report)'s share price rose 8.7% during trading on Tuesday . The stock traded as high as $20.16 and last traded at $19.94. Approximately 301,071 shares changed hands during trading, an increase of 211% from the average daily volume of 96,751 shares. The stock had previously closed at $18.35.

Wall Street Analysts Forecast Growth

Separately, JMP Securities reiterated a "market perform" rating on shares of Inhibrx Biosciences in a research report on Thursday, May 15th.

Inhibrx Biosciences Trading Up 3.3%

The stock has a market capitalization of $313.93 million, a price-to-earnings ratio of 0.19 and a beta of -0.04. The firm has a 50-day moving average of $14.08 and a 200 day moving average of $13.59. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 1.04.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.55) by ($0.25). As a group, equities analysts predict that Inhibrx Biosciences, Inc. will post 104.88 EPS for the current fiscal year.

Institutional Trading of Inhibrx Biosciences

A number of large investors have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. acquired a new stake in shares of Inhibrx Biosciences in the fourth quarter worth $28,000. Strs Ohio acquired a new stake in shares of Inhibrx Biosciences in the 1st quarter valued at $27,000. Natixis acquired a new position in Inhibrx Biosciences during the fourth quarter worth $31,000. State of Wyoming bought a new position in Inhibrx Biosciences during the fourth quarter valued at about $83,000. Finally, Corebridge Financial Inc. bought a new stake in shares of Inhibrx Biosciences during the 4th quarter worth about $89,000. 82.46% of the stock is currently owned by institutional investors.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.